Biotechnology

Sana Biotechnology prepares for its pivotal J.P. Morgan update, balancing groundbreaking diabetes data against a ticking financial clock and fierce competition.

A new AI-powered venture is giving abandoned gene therapies a second chance, challenging traditional pharma models to bring hope to rare disease patients.

From AI-powered diagnostics to non-hallucinogenic psychedelics, 2025's discoveries are redefining mental healthcare and offering new hope.

Scientists unveil a DARPA-funded biofilm that may expel 98% of ingested microplastics, offering a new defense in the fight for human health.

A biotech firm's promising concussion therapy, backed by NFL's Alex Smith, shows an 85% responder rate and now seeks public funding for its final push.

Pharma giant Lilly and AI biotech BigHat are teaming up to solve a critical flaw in AI drug discovery, aiming to unlock a new generation of therapies.

The deal creates an end-to-end commercialization powerhouse, tackling pharma's toughest payer, reimbursement, and patient affordability challenges.

With $16.4M in new funding, STRM.BIO is advancing a novel gene therapy platform that uses natural vesicles to target bone marrow, offering new hope for rare diseases.

Palisade Bio's PALI-2108, a drug targeting IBD at its source, secures a key investment, offering hope for a new era of treatment with fewer side effects.

Health tech firm IMVARIA, maker of an FDA-authorized AI for lung disease, has secured strategic funding from InHealth Ventures and Labcorp to expand its reach.

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

A new patient app from BrightInsight and Sanofi reduced therapy discontinuation by 4%, proving digital tools can solve medicine's adherence problem.

Fresh off its 'Fierce 15' win, Recludix Pharma and its billion-dollar Sanofi pact take the spotlight with a novel oral drug for inflammatory diseases.

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

With a massive $200M Series C, Soley Therapeutics is using its AI cell-sensing platform to fast-track novel cancer drugs from code to clinic.

With its revolutionary Prime Editing tech showing promise, Prime Medicine faces a pivotal moment at the J.P. Morgan conference. Can it justify its new strategy?

With a device that calms deadly 'cytokine storms,' SeaStar Medical targets vast new markets, but can the small company deliver on its huge promises?

Kelonia Therapeutics gets the FDA green light to expand trials for its in vivo CAR-T therapy, a single-infusion treatment that could redefine cancer care.

Azitra will present its novel AI-driven skin therapies for rare diseases at Biotech Showcase, seeking crucial funding and partnerships to advance its pipeline.

As Sotera Health prepares for the J.P. Morgan conference, strong financials clash with legal challenges, putting its mission-critical role under scrutiny.